8-K filing — Beyond Air, Inc. (XAIR)
Filed: 2026-10-08 AccNo: 0001493152-26-046268 Size: 230 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Beyond Air Affirms FY2027 Sales Guidance of $16.000M-$18.000M vs $16.715M Est
Beyond Air (NASDAQ:XAIR) affirms FY2027 sales outlook from $16.000 million-$18.000 million to $16.000 million-$18.000 million vs $16.715 million estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Beyond Air Reports Q2 Preliminary Revenue Of ~$2.3M, Reiterates FY26 Revenue Range $16M - $18M
Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve
Beyond Air New US Patent App #20260284331 Published Today For "METHODS EMPLOYING GASEOUS NITRIC OXIDE FOR INHIBITING TUMOR GROWTH".
https://x.com/US_Patent_Plays/status/2103212175091200022https://ppubs.uspto.gov/pubwebapp/external.html?q=(20260284331).pn